2. Search Result
Search Result
Results for "

neurogenics

" in MedChemExpress (MCE) Product Catalog:

46

Inhibitors & Agonists

4

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14406A
    L-733060 hydrochloride

    		Neurokinin Receptor Neurological Disease Cancer
    L-733060 hydrochloride is a potent tachykinin NK1 receptor antagonist. L-733060 hydrochloride inhibits neurogenic plasma extravasation at doses that do not cause adverse cardiovascular effects in rodents and also acts as an antitumoral agent .
    L-733060 hydrochloride
  • HY-110220
    CIM0216

    		TRP Channel Neurological Disease
    CIM0216, a synthetic TRPM3 ligand, acts as a potent and selective agonist of TRPM3. CIM0216 exhibits selectivity for TRPM3 over TRPM1, TRPM2 and TRPM4-8. CIM0216 acts in a TRPM3-dependent manner to induce pain and evoke neuropeptide release from sensory nerve terminals in vitro. CIM0216 is a powerful tool for studies of the physiological functions of TRPM3, and can be used for neurogenic inflammation research .
    CIM0216
  • HY-13458
    Droxidopa

    L-DOPS; DOPS; SM5688

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
    Droxidopa
  • HY-13999
    NSI-189

    		Others Neurological Disease
    NSI-189, benzylpiperizine-aminiopyridine, is a multi-domain neurogenic compound with brain-therapeutic properties. NSI-189 can stimulate neurogenesis of human hippocampus-derived neural stem cells in vitro and stimulates neurogenesis in murine hippocampus in vivo. NSI-189 can be used for the research of psychiatric disorders .
    NSI-189
  • HY-105192
    CP-122288

    		Others Neurological Disease Inflammation/Immunology
    CP-122288, a highly potent inhibitor of neurogenic inflammation, can be used in migraine study .
    CP-122288
  • HY-P3852
    Neurokinin Receptor (393-407), rat

    SPR393-407

    		 Neurokinin Receptor Neurological Disease Inflammation/Immunology
    Neurokinin Receptor (393-407), rat (SPR393–407) is a rat neurokinin 1 receptor (NK1R) fragment. NK1R is rapidly internalized by endocytosis and recycled to the plasma membrane when binding to substance P (SP). Neurokinin Receptor (393-407), rat can be used in the research of neurogenic inflammation .
    Neurokinin Receptor (393-407), rat
  • HY-108483
    RP 67580

    		Neurokinin Receptor Neurological Disease Inflammation/Immunology
    RP 67580 is a non-peptide antagonist of substance P (SP), competitively inhibits the binding of [3H]SP to neurokinin receptor 1 (NK1 receptor) in rat brain membranes with a Ki value of 4.16 nM. RP 67580 is a specific antagonist of NK1 receptors and can be used in the research of pain and neurogenic inflammation .
    RP 67580
  • HY-19665
    Lanepitant

    LY303870

    		 Neurokinin Receptor Neurological Disease Inflammation/Immunology
    Lanepitant (LY303870) is a selective neurokinin-1 (NK-1) receptor antagonist. Lanepitant blocks neurogenic inflammation and pain transmission by preventing the binding of substance P to NK-1 receptors on both neuronal and non-neuronal tissues. Lanepitant can be used to study osteoarthritis .
    Lanepitant
  • HY-13458A
    Droxidopa hydrochloride

    L-DOPS hydrochloride; DOPS hydrochloride; SM5688 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
    Droxidopa hydrochloride
  • HY-B0267C
    (R)-Oxybutynin

    Aroxybutynin

    		 mAChR Neurological Disease
    (R)-Oxybutynin (Aroxybutynin) is the racemic isomer of Oxybutynin and an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antispasmodic, antimuscarinic, and anticholinergic activities and competitively antagonizes carbachol-induced contractions. (R)-Oxybutynin can be used to study urinary incontinence caused by neurogenic bladder dysfunction .
    (R)-Oxybutynin
  • HY-108482
    CP-96,345

    		Neurokinin Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    CP-96,345 is a specific, highly potent, and orally active tachykinin and substance P receptor non-peptide inhibitor. CP-96,345 prevents the drop in blood pressure evoked by substance P and neurokinin A. CP-96,345 can be used for researching neurogenic inflammation .
    CP-96,345
  • HY-13458R
    Droxidopa (Standard)

    		Adrenergic Receptor Neurological Disease
    Droxidopa (Standard) is the analytical standard of Droxidopa. This product is intended for research and analytical applications. Droxidopa (L-DOPS; SM5688) is a potent, orally active norepinephrine precursor. Droxidopa increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) .
    Droxidopa (Standard)
  • HY-A0039
    Eletriptan

    UK-116044

    		 5-HT Receptor Neurological Disease Inflammation/Immunology
    Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .
    Eletriptan
  • HY-B0267B
    (R)-Oxybutynin hydrochloride

    Aroxybutynin hydrochloride

    		 mAChR Neurological Disease
    (R)-Oxybutynin hydrochloride, a (R)-isomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride has antimuscarinic, antispasmodic and anticholinergic activity, competitively antagonizes Carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used for researching incontinence due to neurogenic bladder dysfunction . (R)-Oxybutynin (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (R)-Oxybutynin hydrochloride
  • HY-P5155
    Stromatoxin 1

    		Potassium Channel Neurological Disease
    Stromatoxin 1 is an inhibitor of Potassium Channel, a peptide which can be isolated from tarantulas. Stromatoxin 1 selectively inhibits K(V)2.1, K(V)2.2, K(V)4.2, and K(V)2.1/9.3 channels. K(V)2.1 and K(V)2.2, but not K(V)4.2, channel subunits play a key role in opposing both myogenic and neurogenic urinary bladder smooth muscle (UBSM) contractions in rats .
    Stromatoxin 1
  • HY-168060
    (8R)-8-Hydroxyepoxyboetirane A

    		PKC Neurological Disease
    (8R)-8-Hydroxyepoxyboetirane A is a neurogenic compound that interacts with PKC δ-C1B. (8R)-8-Hydroxyepoxyboetirane A binds to the PKC enzyme pocket via hydrogen bonds with Gly-253, Leu-251 and Thr242. (8R)-8-Hydroxyepoxyboetirane A induces NRG1 release and differentiation of NSC into neurons. (8R)-8-Hydroxyepoxyboetirane A is promising for research of neurological disorders .
    (8R)-8-Hydroxyepoxyboetirane A
  • HY-B0267BS
    Oxybutynin-d5 hydrochloride

    		mAChR Isotope-Labeled Compounds Neurological Disease
    Oxybutynin-d5 hydrochloride is deuterated labeled (R)-Oxybutynin hydrochloride (HY-B0267B). (R)-Oxybutynin hydrochloride, a (R)-isomer of Oxybutynin hydrochloride, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin hydrochloride has antimuscarinic, antispasmodic and anticholinergic activity, competitively antagonizes Carbachol-induced contractions. (R)-Oxybutynin hydrochloride can be used for researching incontinence due to neurogenic bladder dysfunction . (R)-Oxybutynin hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Oxybutynin-d5 hydrochloride
  • HY-108439
    Neurodazine

    		Wnt Hedgehog Neurological Disease
    Neurodazine is a neurogenic inducer, serve as a promoter of neurogenesisin pluripotent cells. Neurodazine promotes neurogenesis by activating Wnt and Shh signaling pathways. .
    Neurodazine
  • HY-120928
    S 16474

    		Neurokinin Receptor Neurological Disease Inflammation/Immunology
    S 16474 is a cyclic peptide with antagonistic effects on NK1 and NK2 receptors. S 16474 can be used in the study of neurogenic inflammation .
    S 16474
  • HY-119541
    Ampreloxetine

    TD-9855

    		 5-HT Receptor Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Ampreloxetine (TD-9855) is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine has the potential for the research of neurogenic orthostatic hypotension .
    Ampreloxetine
  • HY-119541A
    Ampreloxetine TFA

    TD-9855 TFA

    		 5-HT Receptor Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Ampreloxetine (TD-9855) TFA is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine TFA has the potential for the research of neurogenic orthostatic hypotension .
    Ampreloxetine TFA
  • HY-167836
    BNN-20

    		Trk Receptor Neurological Disease
    BNN-20 is a synthetic microneurotrophin that mimics brain-derived neurotrophic factor (BDNF) and exhibits area-specific pleiotropic neuroprotective and pro-neurogenic effects. BNN-20 can be utilized in research related to Parkinson's disease .
    BNN-20
  • HY-143576
    P2X3 antagonist 37

    		P2X Receptor Neurological Disease
    P2X3 antagonist 37 is a potent P2X3 receptor antagonist with an IC50 of 32.45 nM for hP2X3 (WO2021115225A1, example 68) .
    P2X3 antagonist 37
  • HY-128402
    P2X3-IN-1

    		P2X Receptor Neurological Disease
    P2X3-IN-1 (example 7) is an inhibitor of P2X3 receptor. P2X3-IN-1 can be used for neurogenic diseases research .
    P2X3-IN-1
  • HY-128856
    P7C3-OMe

    		Others Neurological Disease
    P7C3-OMe is a pro-neurogenic compound, has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer .
    P7C3-OMe
  • HY-N8487
    7-Methoxyflavone

    		Others Neurological Disease Inflammation/Immunology
    7-Methoxyflavone is a compound isolated from Zornia brasiliensis. 7-Methoxyflavone has peripheral antinociceptive activity. 7-Methoxyflavone inhibits paw-licking time in the neurogenic phase of the formalin pain response (65.6%) and did not decrease the nociceptive response in the inflammatory phase .
    7-Methoxyflavone
  • HY-15065
    Chembridge-5861528

    TCS 5861528

    		 TRP Channel Neurological Disease Metabolic Disease Inflammation/Immunology
    Chembridge-5861528 (TCS 5861528) is a potent TRPA1 channel antagonist that antagonizes similarly allyl isothiocyanate- and 4-HNE-evoked TRPA1 responses, with IC50 values of 14.3 μM and 18.7 μM, respectively. Chembridge-5861528 shows antihypersensitivity activities .
    Chembridge-5861528
  • HY-10568
    TC-E 5005

    		Phosphodiesterase (PDE) Metabolic Disease
    TC-E 5005 is a potent and selective PDE10A inhibitor with IC50 values of 7.28, 239, 779, 919, 3,100, and 3,700 nM for PDE10A, 2A, 11A, 5A, 7B and 3A, respectively. TC-E 5005 inhibits adrenergic and neurogenic smooth muscle contractions in the human prostate .
    TC-E 5005
  • HY-P5914
    Wasabi Receptor Toxin

    WaTx

    		 TRP Channel Neurological Disease
    Wasabi Receptor Toxin is a cell-penetrating scorpion toxin. Wasabi Receptor Toxin is the activator for TRPA1 ion channel with EC50 in nanomolar level, and prolongs the channel open time, but reduces Ca 2+ permeability. Wasabi Receptor Toxin causes thermal hypersensitivity and mechanical allodynia in rats, without triggering neurogenic inflammation .
    Wasabi Receptor Toxin
  • HY-167741
    Chlorisondamine

    		Others Cardiovascular Disease Neurological Disease
    Chlorisondamine is a nicotinic antagonist that acts as a ganglionic blocker and has been utilized to evaluate the neurogenic contributions to blood pressure and sympathetic vasomotor tone in animal models. Chlorisondamine has demonstrated antihypertensive properties, primarily being assessed through its effects on blood pressure, cardiac output, and heart rate in various experimental settings, particularly in mice.
    Chlorisondamine
  • HY-160980
    Sornidipine

    		Calcium Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Sornidipine is a calcium channel blocker. Sornidipine also reduces neurogenic inflammation. Sornidipine reduces the inflow of calcium ions into cells by blocking L-type calcium channels, thereby reducing the contraction of vascular smooth muscle, leading to vasodilation and decreased blood pressure. Sornidipine can be used to study the cardiovascular system especially in hypertension and related cardiovascular diseases .
    Sornidipine
  • HY-120699
    RO5488608

    		mGluR Neurological Disease
    RO5488608 is a negative allosteric metabotropic modulator of glutamate receptor 2/3. RO5488608 inhibits LY354740 (HY-18941)-induced intracellular Ca 2+ release and can be used for study of antidepressant .
    RO5488608
  • HY-147748
    COX-2-IN-17

    		COX Inflammation/Immunology
    COX-2-IN-17 (compound 10) is a potent and BBB-penetrated COX-2 (cyclooxygenase-2) inhibitor, with an IC50 of 0.02 μM. COX-2-IN-17 shows anti-inflammatory and analgesic activities. COX-2-IN-17 attenuates hyperalgesia in the neurogenic phase as well as the inflammatory phase .
    COX-2-IN-17
  • HY-129047
    Trypsin
    5 Publications Verification

    		 Ser/Thr Protease Protease Activated Receptor (PAR) Infection Inflammation/Immunology
    Trypsin is a serine protease enzyme, and hydrolyzes proteins at the carboxyl side of the Lysine or Arginine. Trypsin activates PAR2 and PAR4. Trypsin induces cell-to-cell membrane fusion in PDCoV infection by the interaction of S glycoprotein of PDCoV and pAPN. Trypsin also promotes cell proliferation and differentiation. Trypsin can be used in the research of wound healing and neurogenic inflammation .
    Trypsin
  • HY-17012
    Dapitant

    RPR 100893

    		 Neurokinin Receptor Inflammation/Immunology
    Dapitant (RPR 100893) is a non-peptide Substance P antagonist with high affinity for the human NK1 receptor. It belongs to the 7,7,4-trimethylperhydroisoindole class of compounds. Dapitant inhibits the binding of Substance P to NK1 receptors, thereby blocking its neurokinin-mediated effects. This novel antagonist represents a potential therapeutic option for conditions involving Substance P, such as neurogenic inflammation and pain modulation .
    Dapitant
  • HY-N13232
    Grape Skin Extract

    		Others Neurological Disease
    Grape Skin Extract is a grape skin extract, and its ingredients include: Polyphenols. Grape Skin Extract has neuroprotective effects and can improve Aβ-induced cytotoxicity to SH-SY5Y cells. Grape Skin Extract can increase the proliferation and memory of neurogenic areas, but reduce the oxidative stress associated with proinflammatory cytokines during aging, thereby protecting neurons. .
    Grape Skin Extract
  • HY-15977
    (S)-P7C3-OMe

    		Others Neurological Disease
    (S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease .
    (S)-P7C3-OMe
  • HY-A0039S1
    Eletriptan-d5

    		5-HT Receptor Inflammation/Immunology
    Eletriptan-d5 is the deuterium labeled Eletriptan[1]. Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine[2].
    Eletriptan-d5
  • HY-A0039S2
    Eletriptan-d5 hydrochloride

    		5-HT Receptor Inflammation/Immunology
    Eletriptan-d5 (hydrochloride) is the deuterium labeled Eletriptan hydrochloride[1]. Eletriptan (UK-116044) hydrochloride is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan hydrochloride has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan hydrochloride can be used for researching migraine[2].
    Eletriptan-d5 hydrochloride
  • HY-129047A
    Trypsin (MS grade)

    		Ser/Thr Protease Protease Activated Receptor (PAR) Infection Inflammation/Immunology
    Trypsin MS grade is a serine protease enzyme, and hydrolyzes proteins at the carboxyl side of the Lysine or Arginine. Trypsin MS grade activates PAR2 and PAR4. Trypsin MS grade induces cell-to-cell membrane fusion in PDCoV infection by the interaction of S glycoprotein of PDCoV and pAPN. Trypsin MS grade also promotes cell proliferation and differentiation. Trypsin MS grade can be used in the research of wound healing and neurogenic inflammation .
    Trypsin (MS grade)
  • HY-P5914A
    Wasabi Receptor Toxin TFA

    WaTx TFA

    		 TRP Channel Neurological Disease
    Wasabi Receptor Toxin TFA (WaTx TFA) is the TFA salt form of Wasabi Receptor Toxin (HY-P5914). Wasabi Receptor Toxin TFA is a cell-penetrating scorpion toxin. Wasabi Receptor Toxin TFA is the activator for TRPA1 ion channel with EC50 in nanomolar level, and prolongs the channel open time, but reduces Ca 2+ permeability. Wasabi Receptor Toxin TFA causes thermal hypersensitivity and mechanical allodynia in rats, without triggering neurogenic inflammation .
    Wasabi Receptor Toxin TFA
  • HY-116522
    AR420626
    3 Publications Verification

    		 Free Fatty Acid Receptor Histone Methyltransferase HDAC mTOR CaMK p38 MAPK Epigenetic Reader Domain GLUT nAChR TNF Receptor Metabolic Disease Inflammation/Immunology Cancer
    AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3) (IC50=117 nM). AR420626 has anti-inflammatory, anticancer and antidiabetic activities. AR420626 improves neurogenic diarrhea by inhibiting nAChR mediated neural pathways. AR420626 inhibits the growth of HepG2 xenografts and inhibits the proliferation of hepatoma cells by inducing apoptosis. AR420626 also suppresses allergic asthma and eczema and has the ability to activate GPR41 to increase Ca 2+ signal-mediated glucose uptake and improve diabetes .
    AR420626
  • HY-147106
    Mrgx2 antagonist-1

    		Mas-related G-protein-coupled Receptor (MRGPR) Cardiovascular Disease Inflammation/Immunology
    Mrgx2 antagonist-1 (example 1) is a potent Mrgx2 (Mas-related Gene X2) antagonist. Mrgx2 antagonist-1 can be used for the research of MrgX2-mediated diseases and disorders.
    Mrgx2 antagonist-1
  • HY-B0229
    Zolmitriptan

    BW-311C90; 311C90

    		 5-HT Receptor Endogenous Metabolite Neurological Disease
    Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .
    Zolmitriptan
  • HY-116408
    Propiverine

    		mAChR Neurological Disease
    Propiverine is a potent antimuscarinic agent. Propiverine inhibits cellular calcium influx, thereby diminishing muscle spasm. Propiverine has neurotropic and musculotropic effects on the urinary bladder smooth muscle. Propiverine can used for overactive bladder (OAB) research .
    Propiverine
  • HY-136625
    LY134046

    		Others Neurological Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.
    LY134046

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: